The company plans to triple its biomanufacturing R&D capacity beyond what it is currently and also develop new software programs. The company has more than 30 customers, ranging from startups to large firms.
With the funding, which came from Section 32, Eniac Ventures and Y Combinator, the company will advance its technology and add new employees to its sales and engineering teams.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
Behind companies like Hims, Nurx and Lemonaid sits Truepill's technology, which handles the logistics, shipping and pharmacy fulfillment necessary to run the direct-to-consumer businesses.
The company's initial program, known as ND-1000, is a combination of an existing generic cancer medication with a natural product that is meant to boost the effectiveness of CAR T-Cell therapy.
The company also appointed to its board former Novartis CEO Joe Jimenez, who was involved with the Swiss drugmaker's hiring of former Trump attorney Michael Cohen.
From early Alzheimer's detection to tracking a cancer patient's treatment response, these five Y Combinator startups are changing the healthcare landscape.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
In a move that will clearly up its focus on RNA diagnostics, St. Louis-based Cofactor Genomics has acquired San Francisco's Narus Biotechnologies.
Anyone remotely close to the healthcare sector knows that HIPAA compliance is nothing to be taken lightly, from the big health systems to the startups looking to tap into potentially vast knowledge gleaned from patient data. And startups in particular face a daunting task convincing the healthcare giants they hope to work with that, while […]
Y Combinator is doing something that technology accelerators, even those planted firmly in the healthcare space, have traditionally avoided. It will invest in biotech startups. Technology accelerators never expressed interest in backing biotechnology companies because drug development takes many years, is capital intensive and a high-risk proposition. But the reward is saved or improved lives, […]